Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE® (trofinetide)
Pipeline
Pipeline
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Hypoxic-ischemic encephalopathy
Prader-Willi Syndrome
Compassionate Use
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2026
2025
2024
2023
2022
2021
2020
2019
Older
Jun 27, 2017
Trading Halt
Jun 02, 2017
Investor presentation, 2 June 2017
May 31, 2017
Neuren announces grant of two new patents to 2032
May 29, 2017
Notice of Annual General Meeting/Proxy Form
May 08, 2017
Response to Appendix 4C Query
Apr 28, 2017
Appendix 4C - quarterly
Apr 28, 2017
Appendix 4G
Apr 28, 2017
Annual Report to shareholders
Apr 04, 2017
Neuren receives $1 million R&D Tax Incentive
Apr 03, 2017
Investor presentation, 3 April 2017
Previous
1
2
3
4
5
Next
